Pneumocystis jirovecii pneumonia overview

Jump to navigation Jump to search

Pneumonia Main Page

Pneumocystis jirovecii pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pneumocystis jirovecii pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pneumocystis jirovecii pneumonia overview On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pneumocystis jirovecii pneumonia overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pneumocystis jirovecii pneumonia overview

CDC on Pneumocystis jirovecii pneumonia overview

Pneumocystis jirovecii pneumonia overview in the news

Blogs on Pneumocystis jirovecii pneumonia overview

Pneumocystis jirovecii pneumonia

Risk calculators and risk factors for Pneumocystis jirovecii pneumonia overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pneumocystis pneumonia (PCP) is a form of pneumonia caused by the yeast-like fungal Pneumocystis jirovecii (Jirovecii is pronounced "yee row vet zee eye"). The causal agent was originally described as a protozoan and spelled P. jiroveci and prior to then was classified as a form of Pneumocystis carinii, a name still in common usage.[1][2] These names are discussed below. As a result, Pneumocystis pneumonia (PCP) has also been known as Pneumocystis jiroveci[i] pneumonia and as Pneumocystis carinii pneumonia, as is also explained below.[3][4][5]

It is relatively rare in people with normal immune systems but common among people with weakened immune systems, such as premature or severely malnourished children, the elderly, and especially AIDS patients, in whom it is most commonly observed today.[6] PCP can also develop in patients who are taking immunosuppressant medications (e.g. patients who have undergone solid organ transplantation) and in patients who have undergone bone marrow transplantation.

The organism is distributed worldwide[7].

References

  1. Stringer JR, Beard CB, Miller RF, Wakefield AE (2002). "A new name (Pneumocystis jiroveci) for Pneumocystis from humans". Emerg Infect Dis. 8 (9): 891–6. PMID 12194762.
  2. Redhead SA, Cushion MT, Frenkel JK, Stringer JR (2006). "Pneumocystis and Trypanosoma cruzi: nomenclature and typifications". J Eukaryot Microbiol. 53 (1): 2–11. PMID 16441572.
  3. Cushion MT . (1998). "Chapter 34. Pneumocystis carinii. In: Collier, L., Balows, A. & Sussman, M. (ed.), Topley and Wilson's Microbiology and Microbial Infections 9th ed. Arnold and Oxford Press, New York": 645–683.
  4. Cushion MT (1998). "Taxonomy, genetic organization, and life cycle of Pneumocystis carinii". Semin. Respir. Infect. 13 (4): 304–312.
  5. Cushion MT (2004). "Pneumocystis: unraveling the cloak of obscurity". Trends Microbiol. 12 (5): 243–249.
  6. Ryan KJ; Ray CG (editors) (2004). Sherris Medical Microbiology (4th ed. ed.). McGraw Hill. ISBN 0838585299.
  7. Morris A; et al. (2004). "Current Epidemiology of Pneumocystis Pneumonia". Emerg Infect Dis. 10 (10): 1713–1720. PMID 15504255.

Template:WH Template:WS